28-day ocular delivery of brimonidine tartrate from rationally designed degradable microparticles in a rabbit model

摘要

The BT-loaded microparticles presented in this study are capable of releasing a therapeutically relevant amount of a common glaucoma medication for over 30 days. Additionally, treatments based on BTMPs demonstrate a significantly greater drop in IOP over the entire 28-day study compared to the baseline IOP in a healthy rabbit model. Subconjunctival injections of the microparticles resulted in neither foreign body response nor infection after the full 28-day experimental period, and microparticles were confined to the injection area. We are currently adapting this controlled-release BT delivery system into a simple, patient-administered formulation that provides the same IOP reduction potential and biocompatibility without the need for intraocular injections.